New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyond

Lung cancer is the leading cause of mortality worldwide. Non-small cell lung cancer (NSCLC) is a particularly aggressive cancer, the optimum management of which is still being determined. In the metastatic disease, the standard therapy is a platinum-based combination chemotherapy; however, in spite...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Therapeutics and clinical risk management 2011-01, Vol.7, p.429-440
Hauptverfasser:	Gori, Bruno, Ricciardi, Serena, Fulvi, Alberto, Intagliata, Salvatore, Del Signore, Ester, de Marinis, Filippo
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiogenesis Cancer therapies FGF Kinases Lung cancer NSCLC oral antiangiogenic agents PDGF Review Vascular endothelial growth factor VEGF
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!